TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the publication of efficacy ...

A large meta-analysis reveals that most antipsychotics achieve near-maximal efficacy at the lower end of recommended dose ranges, typically around 3-5 mg/d of risperidone equivalents.

A final-stage clinical trial comparing a new long-acting, once-weekly pill to treat schizophrenia symptoms with the existing daily treatment has found that both produce comparable therapeutic effects.

Atypical antipsychotic agents, which block postsynaptic dopamine and serotonin receptors, have advantages over traditional antipsychotic medications in the treatment of adults with schizophrenia and ...

In a randomized, double-blind study, we evaluated patients with schizophrenia and a poor response to treatment with clozapine. The patients continued to take clozapine and were randomly assigned to ...

Please provide your email address to receive an email when new articles are posted on . An oral, ultra-long-acting, extended-release risperidone capsule provided sustained therapeutic levels of ...

The antipsychotic cariprazine (Reagila) is not only more effective than risperidone in treating patients with schizophrenia and persistent negative symptoms (PNS), it is also safe and effective for ...

Teva announces positive real-world outcomes for UZEDY® and TEV-'749 in schizophrenia treatment, highlighting improved adherence and reduced hospital visits. Teva Pharmaceuticals has announced positive ...

Risperidone is a second-generation antipsychotic that lacks acute motor side effects at low doses (<6 mg/day), but above this level is associated with parkinsonism and akathesia. The literature ...

An investigational long-acting antipsychotic containing risperidone, known as TV-46000, was able to significantly delay time to relapse in patients with schizophrenia, according to the phase III RISE ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Weekly risperidone delivered via the Lynx platform ...

UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults. 1 This approval marks a ...